Maple Rock Capital Partners’s Prothena Corp PRTA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-373,584
Closed -$13.6M 38
2023
Q4
$13.6M Buy
373,584
+139,000
+59% +$5.35M 0.77% 32
2023
Q3
$11.3M Hold
234,584
1% 25
2023
Q2
$16M Sell
234,584
-59,000
-20% -$3.81M 1.3% 17
2023
Q1
$14.2M Sell
293,584
-105,830
-26% -$5.59M 1.26% 23
2022
Q4
$24.1M Hold
399,414
0.97% 21
2022
Q3
$24.2M Buy
399,414
+65,414
+20% +$2.07M 1.16% 28
2022
Q2
$9.07M Hold
334,000
0.53% 26
2022
Q1
$12.2M Buy
+334,000
New +$12M 0.65% 25

Other funds holding PRTA

Maple Rock Capital Partners's PRTA Position: Q1 2024 in Review

Maple Rock Capital Partners sold out of Prothena Corp (PRTA) in Q1 2024, closing a stake of 373,584 shares — an estimated $13.6M sold.

Maple Rock Capital Partners first reported a position in PRTA in Q1 2022 and held it in 8 quarters. The position peaked at $24.2M in Q3 2022. 169 funds tracked by Wall St. Rank hold PRTA as of Q1 2024.

  • Maple Rock Capital Partners reported no remaining Prothena Corp position as of Q1 2024 after selling out during the quarter.
  • Maple Rock Capital Partners sold 373,584 Prothena Corp shares in Q1 2024, an estimated $13.6M.
  • Maple Rock Capital Partners first reported a position in Prothena Corp in Q1 2022 and held it in 8 quarters.
  • Maple Rock Capital Partners's Prothena Corp position peaked at $24.2M in Q3 2022.
  • 169 funds tracked by Wall St. Rank held Prothena Corp as of Q1 2024.

Based on Maple Rock Capital Partners's 13F filing for Q1 2024, filed 15 May 2024.